Abstract
AN0025 is a selective inhibitor of the prostaglandin E2 type-4 receptor, inhibiting PGE2-mediated differentiation and suppressive function of monocytic myeloid cells, which contribute to the immunosuppressive tumor microenvironment. These cells are associated with a poorer prognosis in many cancers. A previous Ph 1 study with AN0025 was conducted to assess safety, MTD and RP2D. AN0025 was well tolerated in 30 patients with advanced cancer at 125, 250, 500, 750 mg QD with no DLTs. The MTD was not reached.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
